Resultados de Búsqueda por Autor

artículo

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Allia...

Publicado por
de, Azambuja, E, Piccart-Gebhart, M, Fielding, S, Townend, J, Hillman, DW, Colleoni, M, Roylance, R, Kelly, CM, Lombard, J, El-Abed, S, Choudhury, A, Korde, L, Vicente, M, Chumsri, S, Rodeheffer, R, Ellard, SL, Wolff, AC, Holtschmidt, J, Lang, I, Untch, M, Boyle, F, Xu, B, Werutsky, G, Tujakowski, J, Huang, C-S, Baruch, NB, Bliss, J, Ferro, A, Gralow, J, Kim, S-B, Kroep, JR, Krop, I, Kuemmel, S, McConnell, R, Moscetti, L, Knop, AS, van, Duijnhoven, F, Gomez, H, Cameron, D, Di, Cosimo, S, Gelber, RD, Moreno-Aspitia, A

Publicado 2024

Enlace

Background: Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. Here we present the final 10-year analysis of the ALTTO trial. Patients and methods: The ALTTO trial (NCT00490139) is a prospective randomized, phase III, open-label, multicenter study that investigated the role of adjuvant chemotherapy and trastuzumab alone, in combination or sequentially with lapatinib. The primary endpoint was disease-free survival (DFS) and secondary endpoints included overall survival (OS), time to distant recurrence and safety. Results: Overall, 6281 patients with HER2-positive early breast cancer were included in the final efficacy analysis in three treatment groups: trastuzumab (T), lapatinib + trastuzumab (L + T) and trastuzumab followed by lapatinib (T→L). Baseline characteristics were well...

artículo

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

Publicado por
Martín, M, Stecklein, SR, Gluz, O, Villacampa, G, Monte-Millán, M, Nitz, U, Cobo, S, Christgen, M, Brasó-Maristany, F, Álvarez, EL, Echavarría, I, Conte, B, Kuemmel, S, Bueno-Muiño, C, Jerez, Y, Kates, R, Cebollero, M, Kolberg-Liedtke, C, Bueno, O, García-Saenz, JÁ, Moreno, F, Grischke, E-M, Forstbauer, H, Braun, M, Warm, M, Hackmann, J, Uleer, C, Aktas, B, Schumacher, C, Wuerstleins, R, Graeser, M, zu, Eulenburg, C, Kreipe, HH, Gómez, H, Massarrah, T, Herrero, B, Paré, L, Bohn, U, López-Tarruella, S, Vivancos, A, Sanfeliu, E, Parker, JS, Perou, CM, Villagrasa, P, Prat, A, Sharma, P, Harbeck, N

Publicado 2024

Enlace

Background: Identification of biomarkers to optimize treatment strategies for early-stage triple-negative breast cancer (TNBC) is crucial. This study presents the development and validation of TNBC-DX, a novel test aimed at predicting both short- and long-term outcomes in early-stage TNBC. The objective of this study was to evaluate the association between TNBC-DX and efficacy outcomes [pathologic complete response (pCR), distant disease-free survival (DDFS) or event-free survival (EFS), and overall survival (OS)] in the validation cohorts. Methods: Information from 1259 patients with early-stage TNBC (SCAN-B, CALGB-40603, and BrighTNess) was used to establish the TNBC-DX scores. Independent validation of TNBC-DX was carried out in three studies: (i) WSG-ADAPT-TN; (ii) MMJ-CAR-2014-01; and (iii) NeoPACT, including 527 patients with stage I-III TNBC undergoing neoadjuvant chemotherapy. In...